Первичная и вторичная профилактика рака шейки матки (по материалам рекомендаций Американского общества клинической онкологии, март 2017)

1. De Sanjosé S, Temin S, Garland S et al. Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Summary. J Oncol Pract 2017; 25: JOP2017021949. DOI: 10.1200/JOP.2017.021949.
2. Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl. 5): F12–23. DOI: 10.1016/j.vaccine.2012.07.055.
3. Castellsagué X, Alemany L, Quer M et al. HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403, 2016 HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Nat l Cancer Inst 2016; 108 (6): djv403. DOI: 10.1093/jnci/djv403.
4. De Sanjosé S, Serrano B, Castellsagué X et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012; 30 (Suppl. 4): D1–83, vi. DOI: 10.1016/S0264-410X(12)01435-1.
5. De Sanjosé S, Wheeler CM, Quint WG et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer.Cancer Epidemiol Biomarkers Prev 2013; 22 (7): 1313–8. DOI: 10.1158/1055-9965.EPI-13-0053.
6. De Sanjosé S1, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56. DOI: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.
7. Wheeler CM, Castellsagué X, Garland SM et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13 (1): 100–10. DOI: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8.
8. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 5): F123–38. DOI: 10.1016/j.vaccine.2012.04.108.
9. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89 (43): 465–91.
10. Couto E, Sæterdal I, Juvet LK, Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14: 867. DOI: 10.1186/1471-2458-14-867.
11. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommendedhu man papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publications/healthy-living/update recommended-human-papillomavirus-vaccine-immunization-schedule.html
12. Vichnin M, Bonanni P, Klein NP et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34 (9): 983–91. DOI: 10.1097/INF.0000000000000793.
13. Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114 (6): 1179–88. DOI: 10.1097/AOG.0b013e3181c2ca21.
14. Brotherton JM. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013; 347: f5631. DOI: 10.1136/bmj.f5631.
15. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906.
16. Global Advisory Committee on Vaccine Safety, 2–3 December 2015. Wkly Epidemiol Rec 2016; 91 (3): 21–31.
17. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2): 1–24.
18. Chuang LT, Temin S, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2016; 12 (7): 693–6. DOI: 10.1200/JOP.2016.014290. Epub 2016 Jun 21.
19. Jeronimo J, Castle PE, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2017; 13 (2): 129–33. DOI: 10.1200/JOP.2016.017889. Epub 2016 Nov 15.
20. Massad LS, Einstein MH, Huh WK et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121 (4): 829–46. DOI: 10.1097/AOG.0b013e3182883a34.
21. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013.
22. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906.
23. Markowitz LE, Dunne EF, Saraiya M et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63 (RR–05): 1–30.
24. European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS http://www.ema.europa.eu/ema/index. jspcurl5pages/medicines/ human/referrals/Human_papillomavirus _vaccines/ human_referral_prac_ 000053.jsp&mid5 WC0b01ac05805c516f
25. Centers for Disease Control and Prevention, Food and Drug Administration: Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index
26. Garland SM, Stanley M, Brotherton J et al. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2: 9–10, 2016.
27. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices. Am J Transplant 2017; 17 (3): 834–7. DOI: 10.1111/ajt.14206.
28. Garland SM, Subasinghe AK, Jayasinghe YL et al. HPV vaccination for victims of childhood sexual abuse. Lancet 2015; 386 (10007): 1919–20. DOI: 10.1016/S0140-6736(15)00757-6. Epub 2015 Nov 13.
29. Bailey HH, Chuang LT, du Pont NC et al. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34 (15): 1803–12. DOI: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.
30. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 2013; 52 (2): 162–70. DOI: 10.1177/0009922812468208. Epub 2012 Dec 6.
31. Gerend MA, Madkins K, Phillips G, Mustanski B. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. Sex Transm Dis 2016; 43 (3): 185–91. DOI: 10.1097/OLQ.0000000000000408.
32. Gerend MA, Shepherd MA, Lustria ML, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect 2016; 92 (2): 104–7. DOI: 10.1136/sextrans-2015-052088. Epub 2015 Aug 21.
33. Rosenthal SL, Weiss TW, Zimet GD et al. Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's recommendation. Vaccine 2011; 29 (5): 890–5. DOI: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
34. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey. BMC Public Health 2015; 15: 624. DOI: 10.1186/s12889-015-1863-6.
35. Campos NG, Tsu V, Jeronimo J et al: When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 2015; 1: 38–58.
36. National Cancer Institute: Cervical Cancer Screening–Health Professional Version (PDQ®). Bethesda, MD, National Cancer Institute, 2016.
37. Darragh TM, Colgan TJ, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32 (1): 76–115. DOI: 10.1097/PGP.0b013e31826916c7.
38. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156 (12): 880–91, W312. DOI: 10.7326/0003-4819-156-12-201206190-00424.
39. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105 (20): 1550–7. DOI: 10.1093/jnci/djt235. Epub 2013 Oct 4.
40. Qiao YL, Jeronimo J, Zhao FH et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014; 134 (12): 2891–901. DOI: 10.1002/ijc.28616. Epub 2013 Dec 3.
41. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104 (7): 556–65. DOI: 10.1093/jnci/djs135. Epub 2012 Mar 23.
42. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22): 1738–49. DOI: 10.1093/jnci/djs425. Epub 2012 Oct 23.
43. Wentzensen N, Nason M, Schiffman M et al. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 2014; 209 (6): 855–64. DOI: 10.1093/infdis/jit577. Epub 2013 Oct 31.
44. Joste NE, Ronnett BM, Hunt WC et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24 (1): 230–40. DOI: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.
45. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5 (167): 167ra4. DOI: 10.1126/scitranslmed.3004952.

________________________________________________

1. De Sanjosé S, Temin S, Garland S et al. Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Summary. J Oncol Pract 2017; 25: JOP2017021949. DOI: 10.1200/JOP.2017.021949.
2. Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl. 5): F12–23. DOI: 10.1016/j.vaccine.2012.07.055.
3. Castellsagué X, Alemany L, Quer M et al. HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403, 2016 HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Nat l Cancer Inst 2016; 108 (6): djv403. DOI: 10.1093/jnci/djv403.
4. De Sanjosé S, Serrano B, Castellsagué X et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012; 30 (Suppl. 4): D1–83, vi. DOI: 10.1016/S0264-410X(12)01435-1.
5. De Sanjosé S, Wheeler CM, Quint WG et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer.Cancer Epidemiol Biomarkers Prev 2013; 22 (7): 1313–8. DOI: 10.1158/1055-9965.EPI-13-0053.
6. De Sanjosé S1, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048–56. DOI: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.
7. Wheeler CM, Castellsagué X, Garland SM et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13 (1): 100–10. DOI: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8.
8. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 5): F123–38. DOI: 10.1016/j.vaccine.2012.04.108.
9. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89 (43): 465–91.
10. Couto E, Sæterdal I, Juvet LK, Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14: 867. DOI: 10.1186/1471-2458-14-867.
11. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommendedhu man papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publications/healthy-living/update recommended-human-papillomavirus-vaccine-immunization-schedule.html
12. Vichnin M, Bonanni P, Klein NP et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34 (9): 983–91. DOI: 10.1097/INF.0000000000000793.
13. Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114 (6): 1179–88. DOI: 10.1097/AOG.0b013e3181c2ca21.
14. Brotherton JM. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013; 347: f5631. DOI: 10.1136/bmj.f5631.
15. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906.
16. Global Advisory Committee on Vaccine Safety, 2–3 December 2015. Wkly Epidemiol Rec 2016; 91 (3): 21–31.
17. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2): 1–24.
18. Chuang LT, Temin S, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2016; 12 (7): 693–6. DOI: 10.1200/JOP.2016.014290. Epub 2016 Jun 21.
19. Jeronimo J, Castle PE, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2017; 13 (2): 129–33. DOI: 10.1200/JOP.2016.017889. Epub 2016 Nov 15.
20. Massad LS, Einstein MH, Huh WK et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121 (4): 829–46. DOI: 10.1097/AOG.0b013e3182883a34.
21. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013.
22. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. DOI: 10.1136/bmj.f5906.
23. Markowitz LE, Dunne EF, Saraiya M et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63 (RR–05): 1–30.
24. European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS http://www.ema.europa.eu/ema/index. jspcurl5pages/medicines/ human/referrals/Human_papillomavirus _vaccines/ human_referral_prac_ 000053.jsp&mid5 WC0b01ac05805c516f
25. Centers for Disease Control and Prevention, Food and Drug Administration: Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index
26. Garland SM, Stanley M, Brotherton J et al. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2: 9–10, 2016.
27. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices. Am J Transplant 2017; 17 (3): 834–7. DOI: 10.1111/ajt.14206.
28. Garland SM, Subasinghe AK, Jayasinghe YL et al. HPV vaccination for victims of childhood sexual abuse. Lancet 2015; 386 (10007): 1919–20. DOI: 10.1016/S0140-6736(15)00757-6. Epub 2015 Nov 13.
29. Bailey HH, Chuang LT, du Pont NC et al. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34 (15): 1803–12. DOI: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.
30. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 2013; 52 (2): 162–70. DOI: 10.1177/0009922812468208. Epub 2012 Dec 6.
31. Gerend MA, Madkins K, Phillips G, Mustanski B. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. Sex Transm Dis 2016; 43 (3): 185–91. DOI: 10.1097/OLQ.0000000000000408.
32. Gerend MA, Shepherd MA, Lustria ML, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect 2016; 92 (2): 104–7. DOI: 10.1136/sextrans-2015-052088. Epub 2015 Aug 21.
33. Rosenthal SL, Weiss TW, Zimet GD et al. Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's recommendation. Vaccine 2011; 29 (5): 890–5. DOI: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
34. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey. BMC Public Health 2015; 15: 624. DOI: 10.1186/s12889-015-1863-6.
35. Campos NG, Tsu V, Jeronimo J et al: When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 2015; 1: 38–58.
36. National Cancer Institute: Cervical Cancer Screening–Health Professional Version (PDQ®). Bethesda, MD, National Cancer Institute, 2016.
37. Darragh TM, Colgan TJ, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32 (1): 76–115. DOI: 10.1097/PGP.0b013e31826916c7.
38. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156 (12): 880–91, W312. DOI: 10.7326/0003-4819-156-12-201206190-00424.
39. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105 (20): 1550–7. DOI: 10.1093/jnci/djt235. Epub 2013 Oct 4.
40. Qiao YL, Jeronimo J, Zhao FH et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014; 134 (12): 2891–901. DOI: 10.1002/ijc.28616. Epub 2013 Dec 3.
41. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104 (7): 556–65. DOI: 10.1093/jnci/djs135. Epub 2012 Mar 23.
42. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22): 1738–49. DOI: 10.1093/jnci/djs425. Epub 2012 Oct 23.
43. Wentzensen N, Nason M, Schiffman M et al. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 2014; 209 (6): 855–64. DOI: 10.1093/infdis/jit577. Epub 2013 Oct 31.
44. Joste NE, Ronnett BM, Hunt WC et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24 (1): 230–40. DOI: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.
45. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5 (167): 167ra4. DOI: 10.1126/scitranslmed.3004952.

С.О.Дубровина

1 ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России. 44022, Россия, Ростов-на-Дону, пер. Нахичеванский, д. 29;
2 ФГБУ «Ростовский НИИ акушерства и педиатрии» Минздрава России. 344012, Россия, Ростов-на-Дону, ул. Мечникова, д. 43
s.dubrovina@gmail.com

________________________________________________

S.O.Dubrovina

1 Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29;
2 Rostov Research Institute of Obstetrics and Pediatrics of the Ministry of Health of the Russian Federation. 344012, Russian Federation, Rostov-on-Don, ul. Mechnikova, d. 43
s.dubrovina@gmail.com